Testing for Hodgkin’s Lymphoma
Transforming Hodgkin’s Lymphoma Screening with Proactive Diagnostics
Hodgkin’s lymphoma is one of the most treatable cancers when detected early — yet early detection remains a significant challenge. Symptoms such as swollen lymph nodes, fatigue, night sweats, or unexplained weight loss often develop slowly and can easily be mistaken for common infections. As a result, many cases are diagnosed only after the disease has progressed.
Traditional diagnostic methods typically identify lymphoma only after structural abnormalities are visible on imaging or after enlarged lymph nodes are biopsied. As your original document states, “they detect cancer only after visible changes occur”.
Tzar Labs aims to shift this paradigm by introducing a proactive diagnostic approach that identifies cancer risk at the molecular level, long before visible changes occur.
The HrC test represents a new generation of lymphoma screening — one that prioritises prevention, precision, and early action. By analysing cancer‑initiating cells circulating in the bloodstream, the test offers earlier and clearer insights into Hodgkin’s lymphoma risk than conventional methods alone.
Current Methods for Diagnosing Hodgkin’s Lymphoma
Hodgkin’s lymphoma diagnosis in the UK typically involves several established tools used within NHS and private healthcare settings:
Physical Examination
Doctors check for enlarged lymph nodes in the neck, armpits, or groin. However, swelling can be caused by many benign conditions, making early detection difficult.
Blood Tests
Used to assess inflammation, immune activity, and organ function. While helpful, they cannot diagnose lymphoma on their own.
Imaging (X‑ray, CT, PET‑CT)
Scans detect enlarged lymph nodes or organ involvement. These tools only identify lymphoma once structural changes have occurred.
Lymph Node Biopsy
A tissue sample is taken to confirm the presence of Reed–Sternberg cells — the hallmark of Hodgkin’s lymphoma.
These methods are essential in improving outcomes, yet they remain reactive — “they detect cancer only after visible changes occur”.
Limitations of Conventional Lymphoma Screening
Despite their value, traditional diagnostic tools present several challenges that can delay or complicate early detection:
Symptoms Are Often Vague or Misleading
Early lymphoma symptoms mimic common illnesses such as:
- Viral infections
- Glandular fever
- Chronic fatigue
- Autoimmune conditions
This leads to delayed referrals and misses early‑stage cases.
No Routine Screening Programme
Unlike breast or cervical cancer, there is no national screening programme for lymphoma. Most diagnoses occur only after symptoms worsen.
Detection Threshold
Imaging can only identify lymphoma once lymph nodes enlarge or organs are affected. Molecular changes may occur long before these abnormalities are visible.
Reactive Rather Than Proactive
Conventional tests identify lymphoma only after structural abnormalities form, leaving a diagnostic gap during the earliest molecular stages.
False Reassurance
Normal blood tests or early imaging do not always rule out lymphoma, especially in slow‑growing or early‑stage disease.
These limitations highlight the need for a diagnostic tool that identifies cancer risk before visible abnormalities develop.
Why Traditional Blood‑Based Biopsies Cannot Reliably Detect Lymphoma
Blood‑based biopsies (liquid biopsies) have transformed screening for some cancers — but they fall short for lymphoma, especially Hodgkin’s lymphoma. This is due to several biological and technical limitations:
- Lymphoma Does Not Always Shed DNA Into the Bloodstream
Many lymphomas, particularly early‑stage Hodgkin’s lymphoma, remain confined to lymph nodes.
This means:
- Very little tumour DNA enters the bloodstream
- Standard liquid biopsies often return false‑negative results
- Circulating Tumour DNA (ctDNA) Levels Are Extremely Low
Unlike solid tumours that shed DNA into the blood as they grow, lymphoma cells:
- Shed less DNA
- Shed inconsistently
- Shed only at later stages
This makes ctDNA‑based detection unreliable.
- Lymphoma Mutations Are Highly Variable
There is no single mutation or biomarker that reliably identifies Hodgkin’s lymphoma.
Most liquid biopsies rely on:
- Known mutation panels
- Tumour‑specific DNA fragments
But lymphoma’s genetic diversity means these panels often miss early disease.
- Lymphoma Progresses Through Immune‑Driven Pathways
Hodgkin’s lymphoma is unique because:
- Reed–Sternberg cells are rare
- The tumour mass is mostly immune cells reacting to them
This makes it difficult for standard blood tests to detect the cancer’s true origin.
- Early‑Stage Disease Is Almost Invisible to Liquid Biopsy
Because early lymphoma produces:
- Minimal tumour DNA
- No solid mass shedding
- No consistent biomarkers
Traditional blood biopsies cannot reliably detect it.
The HrC Test: A Breakthrough in Early Hodgkin’s Lymphoma Detection
The HrC test overcomes the limitations of traditional blood biopsies by focusing on Cancer Stem Cells (CSCs) — the earliest biological drivers of cancer.
Instead of searching for tumour DNA (which may not be present), the HrC test isolates and analyses CSCs circulating in the bloodstream. These cells appear before tumours form, enlarge, or shed DNA.
A simple 12ml blood sample enables the HrC test to deliver:
A 12–18 Month Early Warning Window
Detection of cancer‑initiating molecular activity long before conventional screening can identify abnormalities.
High Sensitivity and Clear Results
With sensitivity above 90%, the test provides a definitive “Risk” or “No Risk” score, reducing uncertainty and eliminating ambiguous outcomes.
Reliable “Safe Zone” Assessment
A clear indication of “no risk” offers reassurance that Hodgkin’s lymphoma is not present and is unlikely to develop within the next year.
A Non‑Invasive Alternative That Could Improve Early Detection
Because the HrC test requires only a blood sample, it avoids:
- Delayed referrals
- Unnecessary biopsies
- Anxiety associated with ambiguous symptoms
- The wait‑and‑see approach often used in early lymphoma cases
This has the potential to significantly increase early detection rates and reduce diagnostic delays.
This proactive approach empowers individuals with earlier insights and greater control over their long‑term health.
Comprehensive Cancer Screening Through a Single Test
Pan‑Cancer Detection for Complete Health Protection
Although this document focuses on Hodgkin’s lymphoma, the HrC test is designed as a comprehensive pan‑cancer screening tool. Research shows that many major cancers originate from similar stem‑cell‑driven mechanisms. By analysing CSCs, the HrC test can screen for more than 60 different cancers through one blood draw.
Key Advantages Include:
- Holistic Health Monitoring
Simultaneous assessment of lymphoma risk alongside other major cancers such as Bladder, Bowel, Breast, Cervical, Kidney, Leukaemia, Liver, Lung, Ovarian, Pancreatic and Prostate. - Actionable Insights
Early detection supports timely medical evaluation, lifestyle changes, and preventive strategies. - One Test, Broad Coverage
A single, non‑invasive test that enhances long‑term health planning and peace of mind.
Tzar Labs’ mission is to support complete health protection through advanced, accurate, and proactive cancer detection.
About HrC | The Science Behind the Technology | Eligibility Checker | Start Your HrC Journey Here